Adamas Aquires Global Rights to Osmolex ER for Motor Symptoms

Adamas Aquires Global Rights to Osmolex ER for Motor Symptoms

282236

Adamas Aquires Global Rights to Osmolex ER for Motor Symptoms

Adamas Pharmaceuticals has acquired global rights to the Parkinson’s disease medication Osmolex ER (amantadine hydrochloride), used to treat motor symptoms, including those caused by other therapies. The purchase, worth $7.5 million, was part of a settlement agreement with the medicine’s developer, Osmotica Pharmaceutical US, according to a press release. The two companies had been involved in ongoing patent litigation over the therapy. “We are pleased to begin 2021 by adding Osmolex ER to our portfolio,…

You must be logged in to read/download the full post.